StemCell Therapy

Driven to solve your unique challenges.

The biotechnology industry requires sophisticated, mixed-use facilities for product development, manufacturing, and distribution. Effective process-driven engineering coupled with an in-depth understanding of adaptive bioprocess design, and the requirements that impact it, are critical to meeting your unique design needs.

For more than three decades, CRB has specialized in delivering high-quality bioprocess facilities that are safe, reliable, and sustainable. Utilizing state-of-the-art methodologies and practices, we provide services across the entire project lifecycle, from conceptual design through preliminary and detailed design, construction, commissioning, and validation.

Our biotechnology teams are widely acknowledged as some of the top experts in their field.They actively participate in industry committees that help advance the standards andguidelines for biotech facilities and processes. Drawing fromtheunparalleled experience of our team of experts, many of whomhave worked atoperating companies themselves,CRB can provide a deep understanding of clinical, research, and regulatory requirements specific to your facility, as well as the processes that drive your business.

At CRB, we believe every project deserves acustomized approach.We work collaboratively with youtounderstand your needs, andwetailor our world-class expertise to find the right solutions for your technical challenges.Most importantly,we approach your project with the samemindset thatour founders instilled in thiscompany 30+ years ago -- we continually put your interests first. That's why, when partnering with CRB, you can be assured thatyour teamwill never be satisfied untilwe haveachieved success for your business!

Original post:
Biotechnology - crbusa.com

Merriam-Webster defines biotechnology as the manipulation (as through genetic engineering) of living organisms or their components to produce useful usually commercial products (as pest resistant crops, new bacterial strains, or novel pharmaceuticals). Although this definition could broadly cover thousands of years of agriculture and animal breeding, the term biotechnology (often abbreviated as biotech) usually means the gene engineering technology that revolutionized the biological sciences starting with Cohen and Boyers demonstration of DNA cloning in their Stanford lab in 1973.

Since the first DNA cloning experiments over 40 years ago, genetic engineering techniques have developed to create engineered biological molecules, genetically designed microorganisms and cells, ways to find new genes and figure out how they work, and even transgenic animals and plants. In the midst of this bioengineering revolution, commercial applications exploded, and an industry developed around techniques like gene cloning, directed mutagenesis, DNA sequencing, RNA interference, biomolecule labeling and detection, and nucleic acid amplification.

The biotech industry broadly segments into the medical and agricultural markets. Although enterprising biotechnology is also being applied to other exciting areas like the industrial production of chemicals and bioremediation, the use in these areas is still specialized and limited. On the other hand, the medical and agricultural industries have each undergone a biotech revolution with newand often controversial research efforts, development programs, and business strategies to discover, alter, or produce novel biomolecules and organisms using bioengineering.

Biotechnology introduced a whole new approach to drug development that did not easily integrate into the chemically-focused approach most of the established pharmaceutical companies were using. This shift precipitated a rash of start-up companies starting with the founding of Cetus (now part of Novartis Diagnostics) and Genentech in the mid-1970s.

Since there was an established venture capital community for the high-tech industry in Silicon Valley, many of the early biotechnology companies also clustered in the San Francisco Bay Area. Over the years, several hundreds of start-up companies have been founded and hot-spots have also developed in the US around Seattle, San Diego, North Carolina's Research Triangle Park, Boston, and Philadelphia, as well as a number of international locations including areas around Berlin, Heidelberg, and Munich in Germany, Oxford and Cambridge in the UK, and the Medicon Valley in eastern Denmark and southern Sweden.

Medical biotech, with revenues exceeding $150 billion annually, receives the bulk of biotech investment and research dollars. Even the term biotech is often used synonymously with this segment. This part of biotech constellates around the drug discovery "pipeline" that starts with basic research to identify genes or proteins associated with particular diseases which could be used as drug targets and diagnostic markers. Once a new gene or protein target is found, thousands of chemicals are screened to find potential drugs that affect the target.

The chemicals that look like they might work as drugs (sometimes known as "hits") then need to be optimized, checked for toxic side effects, and, finally, tested in clinical trials.

Biotech has been instrumental in the initial drug discovery and screening stages. Most major pharmaceutical companies have active target-discovery research programs heavily reliant on biotechnology, and smaller new companies such as Exelixis, BioMarin Pharmaceuticals, and Cephalon do focused drug discovery and development often using unique proprietary techniques. In addition to direct drug development, there are companies like Abbott Diagnostics and Becton-Dickenson that are looking for ways to use new disease-related genes to create new clinical diagnostics.

A lot of these tests identify the most responsive patients for new drugs coming into the market. Also, supporting research for new drugs is a long list of research and lab supply companies that provide basic kits, reagents, and equipment. For example, companies such as Life Technologies, Thermo-Fisher, Promega and a host of others provide lab tools and equipment for bioscience research, and companies such as Molecular Devices and DiscoveRx provide specially engineered cells and detection systems for screening potential new drugs.

The same biotechnology used for drug development can also improve agricultural and food products. However, unlike with pharmaceuticals, genetic engineering did not generate a rash of new ag-biotech start-ups. The difference may be that, despite the technological leap forward, biotech did not fundamentally change the nature of the agricultural industry. Manipulating crops and livestock to optimize genetics to enhance utility and improve yields has been going on for thousands of years. In a way, bioengineering just provides a convenient new method.

Established agricultural companies, such as Dow and Monsanto, simply integrated biotech into their R&D programs.

Most of the focus on ag-biotech is on crop improvement, which, as a business, has been quite successful. Since the first genetically modified corn was introduced in 1994, transgenic crop staples such as wheat, soybean, and tomatoes have become the norm. Now, more than 90% of US-grown corn, soybeans, and cotton are bioengineered. Although lagging behind bioengineered plants, use of biotechnology for farm animal improvement is also pretty prevalent.

Remember Dolly, the first cloned sheep? That was in 1996. Now animal cloning is common, and it's clear transgenic farm animals are on the immediate horizon based on headlines highlighting recent developments on the Federation of Animal Societies' website. Although genetically modified organisms (GMOs) have generated a lot of controversy in recent years, ag-biotech has become pretty well established. According to the 2011 International Service for the Acquisition of Agri-biotech Applications' (ISAAA) 2011 report, 160 million hectares of GMO crops were planted in 2011 with sales of over $160 billion in engineered grain.

Original post:
Biotechnology and the Biotech Industry

BiotechnologyBiotechnologyJames Watson and the late Francis Crick discovered the structure of DNA in 1953; Watson has spoken in favour of genetic engineering

Biotechnology isn't something new - selective breeding to create more useful varieties of animals and plants is a form of biotechnology that human beings have used for thousands of years.

Biotechnology includes any use of science or technology to alter the characteristics of a particular breed or animal.

Biotechnology can be good or bad for animals - and it may also produce an answer to the ethical problems of experimenting on animals.

Transgenic animals raise a particularly difficult problem.

Newspaper articles about the ethical problems of genetically engineered animals are usually concerned about the danger these animals may pose to human beings (usually to human health), rather than any implications for the animals themselves.

Genetic engineering and selective breeding appear to violate animal rights, because they involve manipulating animals for human ends as if the animals were nothing more than human property, rather than treating the animals as being of value in themselves.

Recent action to allow animals to be patented reinforces the idea of animals as human property, rather than beings in their own right.

Biotechnology can be good for animals. Selective breeding and genetic engineering can benefit animals in many ways:

But biotechnology can also be bad for animals - the good effects for the breeder can offset by painful side-effects for the animals:

Profitability is one of the major drivers of both selective breeding and genetic engineering.

If animal welfare is not to be compromised, research must be restricted by a counter-balancing ethical principle that prevents altering animals in a way that was bad for the animal.

One writer, Bernard Rollin, suggests that a suitable rule to regulate genetic engineering would be this:

This principle can easily be adapted to cover selective breeding.

It's been suggested that genetic engineering may solve all the ethical problems of laboratory experiments on animals.The goal is to create a genetically engineered mammal that lacks sentience, but is otherwise identical to normal experimental animals.

Such an animal could not suffer whatever was done to it, so there should be no ethical difficulty in performing experiments on it.

Ethical problems:

Read more:
BBC - Ethics - Animal ethics: Biotechnology

Editor-in-Chief

Volume Editors

Section Editors

General Preface

Nomenclature Guidelines

Permission Acknowledgments

1.01. Introduction

1.02. Amino Acid Metabolism

Glossary

1.02.1. Introduction

1.02.2. General Properties, Classification, and Structure of Amino Acids

1.02.3. Biosynthesis of Amino Acids

1.02.4. Catabolism of Amino Acids

1.02.5. Important Biomolecules Synthesized from Amino Acids

1.03. Enzyme Biocatalysis

Glossary

1.03.1. Introduction to Enzymes

1.03.2. Enzyme Kinetics

1.03.3. Enzyme Engineering

1.03.4. Enzyme Production

1.03.5. Immobilized Enzymes

1.03.6. Enzyme Applications

1.03.7. Conclusions

1.04. Immobilized Biocatalysts

1.04.1. Introduction: Definitions and Scope

1.04.2. Applications of Immobilized Enzymes

1.04.3. Methods of Enzyme Immobilization

1.04.4. Properties of Immobilized Enzymes

1.04.5. Evaluation of Enzyme Immobilization

1.04.6. Heterogeneous Biocatalysis

1.04.7. Future Prospects for Immobilized Biocatalysts

1.05. Lipids, Fatty Acids

Glossary

1.05.1. Introduction

1.05.2. Structure of Fatty Acids

1.05.3. Nomenclature

1.05.4. Form in the Cell

1.05.5. What Do Lipids Do?

1.05.6. Biosynthesis of Fatty Acids and Lipids

1.05.7. Biochemistry of Lipid Accumulation

1.06. DNA Cloning in Plasmid Vectors

Glossary

1.06.1. Introduction

1.06.2. Cloning Vectors: Replication Origins and Partition Regions

1.06.3. Cloning Vectors: Selection Markers

1.06.4. Preparing DNA Fragments for Ligation

1.06.5. Ligation Systems

1.06.6. Methods of Bacterial and Yeast Transformation

1.06.7. Exploitation of Bacteriophage Packaging for DNA Cloning in Plasmid Vectors

1.06.8. Screening of Plasmid Clones in Bacteria for the Desired Recombinant Plasmids

1.06.9. Vector-Implemented Systems for the Direct Selection of Recombinant Plasmids

1.06.10. Direct Selection of Recombinant Plasmids Involving Restriction Enzyme Digestion of the Ligation Mixture

1.06.11. Particular Features of Oligonucleotides Cloning

1.06.12. Particular Features of Cloning of PCR Amplicons

1.06.13. Introduction of Deletions into Plasmids

1.06.14. Instability of Recombinant Plasmids

1.06.15. DNA Cloning Using Site-Specific Recombination

1.06.16. DNA Cloning Using Homologous (General) Recombination

1.06.17. Employment of Transposons for In Vivo Cloning and Manipulation of Large Plasmids

1.06.18. Conclusion

1.07. Structure and Biosynthesis of Glycoprotein Carbohydrates

Glossary

Acknowledgments

1.07.1. Introduction

1.07.2. Monosaccharide Structure

1.07.3. Oligosaccharide Structure

1.07.4. Biosynthesis of Glycoproteins

1.07.5. Glycosylation of Therapeutic Glycoproteins

1.08. Nucleotide Metabolism

Glossary

1.08.1. Introduction

1.08.2. Synthesis of Phosphoribosyl Diphosphate (PRPP)

1.08.3. Purine Biosynthesis

1.08.4. Pyrimidine Biosynthesis

1.08.5. Nucleoside Triphosphate Formation

1.08.6. Deoxyribonucleotide Biosynthesis

1.08.7. Nucleotide Salvage

1.08.8. Purine and Pyrimidine Catabolism

1.08.9. Regulation of Gene Expression in Bacterial Nucleotide Synthesis

1.08.10. Exploitation of the Knowledge of Nucleotide Metabolism in Biotechnology

1.09. Organic Acids

Glossary

1.09.1. Introduction

1.09.2. Citric Acid

1.09.3. Gluconic Acid

1.09.4. Lactic Acid

1.09.5. Itaconic Acid

1.09.6. Other Acids

1.10. Peptides and Glycopeptides

Glossary

1.10.1. Introduction

1.10.2. Peptide Hormones

1.10.3. Neuropeptides

1.10.4. Antibacterial Peptides

1.10.5. Glycosylation Is a Common and Important Post-Translational Modification of Peptides

1.10.6. Common Glycosidic Linkages

1.10.7. Peptide Synthesis

1.10.8. Glycopeptide Synthesis

1.10.9. Peptides and Glycopeptides as Models of Proteins and Glycoproteins

1.10.10. Application of Synthetic Peptides and Glycopeptides for the Treatment of Disease

View post:
Comprehensive Biotechnology - 2nd Edition

Biotechnology, the use of biology to solve problems and make useful products. The most prominent area of biotechnology is the production of therapeutic proteins and other drugs through genetic engineering.

People have been harnessing biological processes to improve their quality of life for some 10,000 years, beginning with the first agricultural communities. Approximately 6,000 years ago, humans began to tap the biological processes of microorganisms in order to make bread, alcoholic beverages, and cheese and to preserve dairy products. But such processes are not what is meant today by biotechnology, a term first widely applied to the molecular and cellular technologies that began to emerge in the 1960s and 70s. A fledgling biotech industry began to coalesce in the mid- to late 1970s, led by Genentech, a pharmaceutical company established in 1976 by Robert A. Swanson and Herbert W. Boyer to commercialize the recombinant DNA technology pioneered by Boyer and Stanley N. Cohen. Early companies such as Genentech, Amgen, Biogen, Cetus, and Genex began by manufacturing genetically engineered substances primarily for medical and environmental uses.

For more than a decade, the biotechnology industry was dominated by recombinant DNA technology, or genetic engineering. This technique consists of splicing the gene for a useful protein (often a human protein) into production cellssuch as yeast, bacteria, or mammalian cells in culturewhich then begin to produce the protein in volume. In the process of splicing a gene into a production cell, a new organism is created. At first, biotechnology investors and researchers were uncertain about whether the courts would permit them to acquire patents on organisms; after all, patents were not allowed on new organisms that happened to be discovered and identified in nature. But, in 1980, the U.S. Supreme Court, in the case of Diamond v. Chakrabarty, resolved the matter by ruling that a live human-made microorganism is patentable subject matter. This decision spawned a wave of new biotechnology firms and the infant industrys first investment boom. In 1982 recombinant insulin became the first product made through genetic engineering to secure approval from the U.S. Food and Drug Administration (FDA). Since then, dozens of genetically engineered protein medications have been commercialized around the world, including recombinant versions of growth hormone, clotting factors, proteins for stimulating the production of red and white blood cells, interferons, and clot-dissolving agents.

In the early years, the main achievement of biotechnology was the ability to produce naturally occurring therapeutic molecules in larger quantities than could be derived from conventional sources such as plasma, animal organs, and human cadavers. Recombinant proteins are also less likely to be contaminated with pathogens or to provoke allergic reactions. Today, biotechnology researchers seek to discover the root molecular causes of disease and to intervene precisely at that level. Sometimes this means producing therapeutic proteins that augment the bodys own supplies or that make up for genetic deficiencies, as in the first generation of biotech medications. (Gene therapyinsertion of genes encoding a needed protein into a patients body or cellsis a related approach.) But the biotechnology industry has also expanded its research into the development of traditional pharmaceuticals and monoclonal antibodies that stop the progress of a disease. Such steps are uncovered through painstaking study of genes (genomics), the proteins that they encode (proteomics), and the larger biological pathways in which they act.

In addition to the tools mentioned above, biotechnology also involves merging biological information with computer technology (bioinformatics), exploring the use of microscopic equipment that can enter the human body (nanotechnology), and possibly applying techniques of stem cell research and cloning to replace dead or defective cells and tissues (regenerative medicine). Companies and academic laboratories integrate these disparate technologies in an effort to analyze downward into molecules and also to synthesize upward from molecular biology toward chemical pathways, tissues, and organs.

In addition to being used in health care, biotechnology has proved helpful in refining industrial processes through the discovery and production of biological enzymes that spark chemical reactions (catalysts); for environmental cleanup, with enzymes that digest contaminants into harmless chemicals and then die after consuming the available food supply; and in agricultural production through genetic engineering.

Agricultural applications of biotechnology have proved the most controversial. Some activists and consumer groups have called for bans on genetically modified organisms (GMOs) or for labeling laws to inform consumers of the growing presence of GMOs in the food supply. In the United States, the introduction of GMOs into agriculture began in 1993, when the FDA approved bovine somatotropin (BST), a growth hormone that boosts milk production in dairy cows. The next year, the FDA approved the first genetically modified whole food, a tomato engineered for a longer shelf life. Since then, regulatory approval in the United States, Europe, and elsewhere has been won by dozens of agricultural GMOs, including crops that produce their own pesticides and crops that survive the application of specific herbicides used to kill weeds. Studies by the United Nations, the U.S. National Academy of Sciences, the European Union, the American Medical Association, U.S. regulatory agencies, and other organizations have found GMO foods to be safe, but skeptics contend that it is still too early to judge the long-term health and ecological effects of such crops. In the late 20th and early 21st centuries, the land area planted in genetically modified crops increased dramatically, from 1.7 million hectares (4.2 million acres) in 1996 to 160 million hectares (395 million acres) by 2011.

Overall, the revenues of U.S. and European biotechnology industries roughly doubled over the five-year period from 1996 through 2000. Rapid growth continued into the 21st century, fueled by the introduction of new products, particularly in health care.

See original here:
biotechnology | Definition, Examples, & Applications ...

Biotechnology is one of the most progressive and beneficial scientific advances of the last quarter century. An interdisciplinary field that includes mathematics, physics, chemistry, engineering and others, it combines various- technologies to either create a new product or modify an existing one to suit our needs.

Its widespread application across multiple industries like food, pharmaceutical, chemical, bio-products, textiles, medicine, nutrition, environmental conservation and animal sciences makes a career in biotechnology one of the fastest growing fields with ample opportunities for qualified professionals.

Biotechnology combines the theoretical (genetics, molecular biology, biochemistry, embryology and cell biology), and the practical (chemical engineering, information technology and robotics)scientific aptitude, a keen interest in the biological sciences, problem solving skills. An analytical mind is essential for successful career in biotechnology.

The candidate should be methodical and patient by nature, able to work neatly and accurately and have a flair for laboratory work. The ability to work independently is another important aspect. The knowledge of computers is a must.

10 + 2 science stream graduates can opt for a B.Tech (Biotechnology) or an integrated M. Tech (Biotechnology); science stream graduates from any field (engineering, medicine etc.) can opt for a M. Tech (Biotechnology).

IIT Delhi and Kharagpur offer admission into a five year integrated M.Tech through a Joint Entrance Examination.

The Jawaharlal Nehru University, New Delhi conducts an all-India entrance examination for their Msc Biotechnology program.

Any candidate with an undergraduate degree from a 10+2+3 system with at least 55% marks in:

Is eligible to apply for the JNU Msc(Biotechnology) as well as others.

The Department of Biotechnology (DBT) also offers postgraduate courses in selected institutions, and through four prominent research institutes, further provides a two-year support for post doctoral programs; the objective is to prepare long term biotech professionals and scientists for frontier research and advance research methodologies.

Two other institutes, backed by the DBT, provide a one-year MD/MS training in medical biotech. The cover fields such as:

SRM University offers B.Tech in Biotechnology, Genetic Engineering, and Bioinformatics. They also offer an M.Tech in Biotechnology and Biomedical Engineering.

Applications Forms Now Available

Affordable and intelligent R&D partnering with Chinese and American corporate bodies has great scope in mining Indias biotech potential and co-developing tech; India has a global market worth a $91 billion. Thats why so many global pharma companies are flocking to India for their own R&D initiatives.

A bio-technologist may find jobs in various quarters. Biotechnology jobs in India can be found in the following fields:

While government institutes and organizations, such as Department of Biotechnology (DBT), several agriculture, dairy and horticulture institutes may offer job opportunities to Biotechnology professionals, one can expect the best salary in private sector.

Drug companies in biotechnology like Dabur, Ranbaxy, Hindustan Lever and Dr Reddy's Labs that have their R & D units offer Biotechnology professionals with handsome pay-packages. There are also ample opportunities available to bio-technologists in the food processing industry, chemical industry and the textile industry.

Some industries employ bio-technologists in their marketing divisions to develop business in sectors where their products would be required.

The major companies, hiring bio-technologists, include Hindustan Lever, Thapar Group, Indo American Hybrid Seeds, Bincon India Ltd., IDPL and Hindustan Antibiotics.

The Government of India provides large-scale employment to most bio-technologists in its research laboratories. Those employed as researchers in government sector can have a starting salary of Rs. 9000 per month along with government perks/allowances.

Private sector pharmaceutical companies generally offer salary between Rs. 12,000- Rs. 20,000 per month to an entry-level postgraduate. A skilled and experienced bio-technologist can get salaries far beyond his expectations.

Indian Institute Of Technology

Indian Institute Of Technology

Vellore Institute Of Technology

Indian Institute Of Technology, Guwahati

National Institute Of Technology, Warangal

PSG College Of Technology

National Institute Of Technology, Durgapur

Manipal Institute Of Technology

BMS College of Engineering

Chaitanya Bharathi Institute of Technology

PES Institute of Technology

SASTRA University

National Institute of Technology, Raipur

GITAM University

Karunya University

Note: Selection through All India Combined Entrance Test

Courses Offered : B.Tech in Biotechnology, Genetic Engineering, and Bioinformatics. M.Tech in Biotechnology and Biomedical Engineering

Visit link:
Biotechnology Career | Jobs, Salary, Courses & Colleges in ...

Sessions and Tracks

Track 1:Pharmaceutical Biotechnology and Drug Design

Pharmaceutical Biotechnology is the science that covers all technologies required for producing, manufacturing and registration of biological drugs. Pharmaceutical companies use biotechnology for manufacturing drugs, pharmacogenomics, gene therapy, and genetic testing. Biotech companies make biotechnology products by manipulating and modifying organisms, usually at molecular level. Pharmaceutical Biotechnology is an increasingly important area of science and technology. It contributes in design and delivery of new therapeutic drugs, diagnostic agents for medical tests, and in gene therapy for correcting the medical symptoms of hereditary diseases. The Pharmaceutical Biotechnology is widely spread, ranging from many ethical issues to changes in healthcare practices and a significant contribution to the development of national economy. Euro Biotechnology 2018 will focus on Biopharmaceuticals Discovery, Biopharmaceutical Regulations and Validations, Biologics and Biosimilars and Clinical Research/Clinical trials, Biotechnology Conferences.

Related: Pharmaceutical Biotechnology Conferences | Molecular Biology Conferences | Biotechnology Conferences 2018 | Biotechnology Conferences | Biotechnology Conferences 2018 USA | Biotechnology Conferences| Biopharmaceutical Conferences | Biotechnology Conferences.

7th World Congress on Mass Spectrometry June 20-22, 2018 Rome, Italy ; 23rd International Pharmaceutical BiotechnologyConferences December 10-11, 2018 Rome, Italy ; 18th World Pharma Congress October 18-20, 2018 Warsaw, Poland ;16th International Conference and Exhibition on Pharmaceutical Formulations July 26-27, 2018 Rome, Italy ; 17th Annual Congress on Pharmaceutics & Drug Delivery Systems September 20-22, 2018 Prague, Czech Republic;16th Annual European Pharma Congress May 20-21, 2019 Zurich, Switzerland ; Pharma Serialisation Summit June 19-21, 2018 Zurich, Switzerland ; European Congress on Pharma August 13-14 , 2018 Paris, France ; Pharma R&D March 04-06, 2019 Paris, France ; 6th Asia Pacific Biotechnology Conferences August 15-16, 2018 Singapore; 22nd World Congress on Biotechnology July 10-11, 2018 Bangkok, Thailand; 18th European Conferences on Biotechnology July 1 - 4, 2018 Geneva, Switzerland,Biotechnology Conferences.

Related Societies:

Europe:

Spanish Society of Biotechnology, The Pharmaceutical Society of Ireland, Russian Medical Society, Society for Engineering in Agriculture, Society of Microbial Ecology and Disease, Manchester University Pharmaceutical Society, Italian Society of Biochemistry and Molecular Biology, European Society for Precision Engineering and Nanotechnology, Society for Chemical Engineering Biotechnology, Romanian Society of Medical Mycology and Mycotoxicology, New Zealand Plant Protection Society, International Society for Pharmaceutical Engineering, Pharmaceutical Society of Australia,Biotechnology Conferences.

USA:Mexican Society for Biotechnology and Bioengineering, Society for Biological Engineering, National Society of Agriculture, The Protein Society, Pharmaceutical Marketing Society,Biotechnology Conferences.

Asia:

Korean Society of Food Science And Technology, Pharmaceutical Society of Singapore, Korean Society of Gene and Cell Therapy, Pharmaceutical Society of Singapore, Indian Society of Nano science And Nanotechnology, Tanta Pharmaceutical Scientific Society (TPSS), Iran Society for Cell Biology, Israel Societies for Experimental Biology, Society for Industrial Microbiology and Biotechnology (SIMB), Malaysian Pharmaceutical Society, Japanese Society for Quantitative Biology, Society for Biotechnology,Biotechnology Conferences.

Track 2 : Microbial Biotechnology

Microbial biotechnology, enabled by genome studies, will lead to breakthroughs such as improved vaccines and better disease-diagnostic tools, improved microbial agents for biological control of plant and animal pests, modifications of plant and animal pathogens for reduced virulence, development of new industrial catalysts and fermentation organisms, and development of new microbial agents for bioremediation of soil and water contaminated by agricultural runoff,Biotechnology Conferences.

Related: Microbial | Biotechnology Conferences | Molecular Biology Conferences | Biotechnology Conferences 2018 | Biotechnology Conferences | Biotechnology Conferences 2018 USA | Biotechnology Conferences| Biopharmaceutical Conferences |Biotechnology Conferences.

Annual Industrial Biotechnology and Bioprocessing Congress September 17-18, 2018 San Diego, California, USA; 3th International Conference on Microbial Interactions & Microbial Ecology July 19-20, 2018 Rome, Italy; Applied Microbiology October 15-16, 2018 Ottawa, Canada and Microbial Biotechnology October 15-16, 2018 Ottawa, Canada ; 12th World Congress on Biotechnology June 28-29, 2018 Amsterdam, Netherlands and 12th World Congress on Microbiology June 28-29, 2018 Amsterdam, Netherlands ; European Congress on Pharma August 13-14 , 2018 Paris, France ; Pharma R&D March 04-06, 2019 Paris, France ; 6thAsia Pacific Biotechnology ConferencesAugust 15-16, 2018 Singapore; 22ndWorld Congress on BiotechnologyJuly 10-11, 2018Bangkok,Thailand;18thEuropean Conferences on BiotechnologyJuly 1 - 4, 2018 Geneva, Switzerland,Biotechnology Conferences; 5th World Congress on Microbial Biotechnology September 17-18, 2018 Lisbon, Portugal,

Related Societies:

Europe:

Spanish Society of Biotechnology, The Pharmaceutical Society of Ireland, Russian Medical Society, Society for Engineering in Agriculture, Society of Microbial Ecology and Disease, Manchester University Pharmaceutical Society, Italian Society of Biochemistry and Molecular Biology, European Society for Precision Engineering and Nanotechnology, Society for Chemical Engineering Biotechnology, Romanian Society of Medical Mycology and Mycotoxicology, New Zealand Plant Protection Society, International Society for Pharmaceutical Engineering, Pharmaceutical Society of Australia,Biotechnology Conferences.

USA:

Mexican Society for Biotechnology and Bioengineering, Society for Biological Engineering, National Society of Agriculture, The Protein Society, Pharmaceutical Marketing Society,Biotechnology Conferences.

Asia:

Korean Society of Food Science And Technology, Pharmaceutical Society of Singapore, Korean Society of Gene and Cell Therapy, Pharmaceutical Society of Singapore, Indian Society of Nano science And Nanotechnology, Tanta Pharmaceutical Scientific Society (TPSS), Iran Society for Cell Biology, Israel Societies for Experimental Biology, Society for Industrial Microbiology and Biotechnology (SIMB), Malaysian Pharmaceutical Society, Japanese Society for Quantitative Biology, Society for Biotechnology,Biotechnology Conferences.

Track 3: Nano Biotechnology

Nano Biotechnology is a discipline in which tools from nanotechnology are developed and applied to study biological phenomena. Nano biotechnology, bio nanotechnology, and Nano biology are terms that refer to the intersection of nanotechnology and biology. Bio nanotechnology and Nano biotechnology serve as blanket terms for various related technologies. The most important objectives that are frequently found in Nano biology involve applying Nano tools to relevant medical/biological problems and refining these applications. Developing new tools, such as peptide Nano sheets, for medical and biological purposes is another primary objective in nanotechnology,Biotechnology Conferences.

Related : Nano Biotechnology Conferences | Molecular Biology Conferences | Nano Biology Conferences | Biotechnology Conferences 2018 | Biotechnology Conferences | Biotechnology Conferences 2018 USA | Biotechnology Conferences|Biotechnology Conferences.

8th International Conference and Expo on Nanosciences Nov 26-28,2018 Barcelona, Spain; 24th World Nano Conference May 07-08, 2018 Rome, Italy; World Congress on Nano medicine September 17-19, 2018 Abu Dhabi, UAE; World Congress on Nanotechnology in Healthcare September 17-19, 2018 Abu Dhabi, UAE; Advanced Nanotechnology October 04-05 2018 Moscow, Russia; 8th International Conference and Expo on Nanotechnology Nov 26-28,2018 Barcelona, Spain ; International Conference On Nanomedicine And Nanobiotechnology September 26-28, 2018 Rome ; Nanotech & Nanobiotechnology July 12-13, 2018 Paris, France ; 4th International Conference On Nanobiotechnology April 9 - 11, 2019 Rome, Italy, 18thEuropean Congress on BiotechnologyJuly 1 - 4, 2018 Geneva, Switzerland,Biotechnology Conferences.

Related Societies:

Europe:

Spanish Society of Biotechnology, The Pharmaceutical Society of Ireland, Russian Medical Society, Society for Engineering in Agriculture, Society of Microbial Ecology and Disease, Manchester University Pharmaceutical Society, Italian Society of Biochemistry and Molecular Biology, European Society for Precision Engineering and Nanotechnology, Society for Chemical Engineering Biotechnology, Romanian Society of Medical Mycology and Mycotoxicology, New Zealand Plant Protection Society, International Society for Pharmaceutical Engineering, Pharmaceutical Society of Australia,Biotechnology Conferences.

USA:

Mexican Society for Biotechnology and Bioengineering, Society for Biological Engineering, National Society of Agriculture, The Protein Society, Pharmaceutical Marketing Society,Biotechnology Conferences.

Asia:

Korean Society of Food Science And Technology, Pharmaceutical Society of Singapore, Korean Society of Gene and Cell Therapy, Pharmaceutical Society of Singapore, Indian Society of Nano science And Nanotechnology, Tanta Pharmaceutical Scientific Society (TPSS), Iran Society for Cell Biology, Israel Societies for Experimental Biology, Society for Industrial Microbiology and Biotechnology (SIMB), Malaysian Pharmaceutical Society, Japanese Society for Quantitative Biology, Society for Biotechnology,Biotechnology Conferences.

Track 4: Stem Cell Biotechnology and Regenerative Medicine

Stem cell biotechnology is a field of biotechnology that develops tools and therapeutics through modification and engineering of stem cells. Stem cell biotechnology is important in regenerative medicine. Regenerative medicine is an Inter disciplinary branch that tends to repair or regenerate damaged cells or tissues to regain or restore their normal function,Biotechnology Conferences.

Related: Stem cell Conferences | Regenerative Medicine Conference | Biotechnology Conference | | Biotechnology Conferences 2018 | Biotechnology Conferences | Biotechnology Conferences 2018 USA | Biotechnology Conferences|Biotechnology Conferences.

12th Annual Conference on Stem Cell and Regenerative Medicine June 04-06, 2018 Prague, Czech Republic ; 10th Annual Conference on Stem Cell and Regenerative Medicine October 08-09, 2018 Zurich, Switzerland ; World Congress and Expo on Cell & Stem Cell Research September 13-15, 2018 Paris, France ; 11th Annual Conference on Stem Cell and Regenerative Medicine October 15-16, 2018 Helsinki, Finland ; International Conference On Cell and Stem Cell Research August 17-18, 2018 Singapore ; Modeling Cell-Cell Interactions Governing Tissue Repair and Disease August 19 - 24, 2018 ; Stem Cell Conference Basel 2018 August 29-31, 2018 Basel, Switzerland; 6th Asia Pacific Biotechnology Conferences August 15-16, 2018 Singapore; 22nd World Congress on Biotechnology July 10-11, 2018 Bangkok, Thailand, 18thEuropean BiotechnologyConferencesJuly 1 - 4, 2018 Geneva, Switzerland,Biotechnology Conferences.

Related Societies:

Europe:

Spanish Society of Biotechnology, The Pharmaceutical Society of Ireland, Russian Medical Society, Society for Engineering in Agriculture, Society of Microbial Ecology and Disease, Manchester University Pharmaceutical Society, Italian Society of Biochemistry and Molecular Biology, European Society for Precision Engineering and Nanotechnology, Society for Chemical Engineering Biotechnology, Romanian Society of Medical Mycology and Mycotoxicology, New Zealand Plant Protection Society, International Society for Pharmaceutical Engineering, Pharmaceutical Society of Australia.,Biotechnology Conferences.

USA:

Mexican Society for Biotechnology and Bioengineering, Society for Biological Engineering, National Society of Agriculture, The Protein Society, Pharmaceutical Marketing Society,Biotechnology Conferences.

Asia:

Korean Society of Food Science And Technology, Pharmaceutical Society of Singapore, Korean Society of Gene and Cell Therapy, Pharmaceutical Society of Singapore, Indian Society of Nano science And Nanotechnology, Tanta Pharmaceutical Scientific Society (TPSS), Iran Society for Cell Biology, Israel Societies for Experimental Biology, Society for Industrial Microbiology and Biotechnology (SIMB), Malaysian Pharmaceutical Society, Japanese Society for Quantitative Biology, Society for Biotechnology,Biotechnology Conferences.

Track 5: Medical Biotechnology

Medical Biotechnology is the use of living cells and cell materials to research and produce pharmaceutical and diagnostic products that help treat and prevent human diseases. leading to the development of several innovative techniques for preventing, diagnosing, and treating diseases,Biotechnology Conferences.

Related: Medical Biotechnology Conferences | Biotechnology Conference | Regenerative conferences | Biotechnology Conferences 2018 | Biotechnology Conferences | Biotechnology Conferences 2018 USA | Biotechnology Conferences|Biotechnology Conferences.

11th International Conference on Tissue Engineering & Regenerative Medicine October 18-20, 2018 Rome, Italy; 12th World Conference on Human Genomics and Genomic MedicineApril 22-23, 2019 Abu Dhabi, UAE; 4th International Conference on Advances in Biotechnology and Bioscience November 15-17, 2018 Frankfurt, Germany ; 11th International Conference on Tissue Engineering & Regenerative Medicine October 18-20, 2018 Rome, Italy ; Medical Biotechnology May 24-25, 2018 Ghent, Belgium ; 6th Asia Pacific Biotechnology Conferences August 15-16, 2018 Singapore; 22nd World Congress on Biotechnology July 10-11, 2018 Bangkok, Thailand,18th European BiotechnologyConferences July 1 - 4, 2018 Geneva, Switzerland,Biotechnology Conferences.

Related Societies:

Europe:

Spanish Society of Biotechnology, The Pharmaceutical Society of Ireland, Russian Medical Society, Society for Engineering in Agriculture, Society of Microbial Ecology and Disease, Manchester University Pharmaceutical Society, Italian Society of Biochemistry and Molecular Biology, European Society for Precision Engineering and Nanotechnology, Society for Chemical Engineering Biotechnology, Romanian Society of Medical Mycology and Mycotoxicology, New Zealand Plant Protection Society, International Society for Pharmaceutical Engineering, Pharmaceutical Society of Australia,Biotechnology Conferences.

USA:

Mexican Society for Biotechnology and Bioengineering, Society for Biological Engineering, National Society of Agriculture, The Protein Society, Pharmaceutical Marketing Society,Biotechnology Conferences.

Asia:

Korean Society of Food Science And Technology, Pharmaceutical Society of Singapore, Korean Society of Gene and Cell Therapy, Pharmaceutical Society of Singapore, Indian Society of Nano science And Nanotechnology, Tanta Pharmaceutical Scientific Society (TPSS), Iran Society for Cell Biology, Israel Societies for Experimental Biology, Society for Industrial Microbiology and Biotechnology (SIMB), Malaysian Pharmaceutical Society, Japanese Society for Quantitative Biology, Society for Biotechnology.

Track 6: Oncolytic Biotechnology

Oncolytic Biotechnology is the study of oncolytic virus, the virus that preferentially infects and kills cancer cells. As the infected cancer cells are destroyed by oncolysis, they release new infectious virus particles or virions to help destroy the remaining tumour. Oncolytic viruses are thought not only to cause direct destruction of the tumour cells, but also to stimulate host anti-tumour immune responses,Biotechnology Conferences.

Related: Cancer Biotechnology Conferences | Biotechnology Conference | Regenerative conferences | Biotechnology Conferences 2018 | Biotechnology Conferences | Biotechnology Conferences 2018 USA | Biotechnology Conferences|Biotechnology Conferences.

11th International Virology and Microbiology July 27-28, 2018 Vancouver, Canada ; 11th World Congress on Virology and Infectious Diseases May 17-18, 2018 Tokyo, Japan ; 2nd International Conference on Cancer Biology, Therapeutics and Drug Discovery & Delivery October 03-04, 2018 Los Angeles, California, USA ; Beatson International Cancer Conference July 01- 04, 2018 Glasgow, Scotland ; 36th World Cancer Conference October 11-13, 2018 Zurich, Switzerland; 6th Asia Pacific Biotechnology Conferences August 15-16, 2018 Singapore; 22nd World Congress on Biotechnology July 10-11, 2018 Bangkok, Thailand, 18thEuropean BiotechnologyConferences July 1 - 4, 2018 Geneva, Switzerland,Biotechnology Conferences.

Related Societies:

Europe:

Spanish Society of Biotechnology, The Pharmaceutical Society of Ireland, Russian Medical Society, Society for Engineering in Agriculture, Society of Microbial Ecology and Disease, Manchester University Pharmaceutical Society, Italian Society of Biochemistry and Molecular Biology, European Society for Precision Engineering and Nanotechnology, Society for Chemical Engineering Biotechnology, Romanian Society of Medical Mycology and Mycotoxicology, New Zealand Plant Protection Society, International Society for Pharmaceutical Engineering, Pharmaceutical Society of Australia,Biotechnology Conferences.

USA:

Mexican Society for Biotechnology and Bioengineering, Society for Biological Engineering, National Society of Agriculture, The Protein Society, Pharmaceutical Marketing Society,Biotechnology Conferences.

Asia:

Korean Society of Food Science And Technology, Pharmaceutical Society of Singapore, Korean Society of Gene and Cell Therapy, Pharmaceutical Society of Singapore, Indian Society of Nano science And Nanotechnology, Tanta Pharmaceutical Scientific Society (TPSS), Iran Society for Cell Biology, Israel Societies for Experimental Biology, Society for Industrial Microbiology and Biotechnology (SIMB), Malaysian Pharmaceutical Society, Japanese Society for Quantitative Biology, Society for Biotechnology,Biotechnology Conferences.

Track 7: Molecular Biotechnology and Genetics

Molecular biotechnology is the use of laboratory techniques to study and modify nucleic acids and proteins for applications in areas such as human and animal health, agriculture, and the environment. Molecular biotechnology results from the convergence of many areas of research, such as molecular biology, microbiology, biochemistry, immunology, genetics, and cell biology. It is an exciting field fueled by the ability to transfer genetic information between organisms with the goal of understanding important biological processes or creating a useful product. The tools of molecular biotechnology can be applied to develop and improve drugs, vaccines, therapies, and diagnostic tests that will improve human and animal health. Molecular biotechnology has applications in plant and animal agriculture, aquaculture, chemical and textile manufacturing, forestry, and food processing.

Related: Molecular Biotechnology Conferences | Biotechnology Conference | Regenerative conferences | Biotechnology Conferences 2018 | Biotechnology Conferences | Biotechnology Conferences 2018 USA | Biotechnology Conferences|Biotechnology Conferences.

Biochemistry & Molecular Biology October 11-12, 2018 Amsterdam, Netherlands ; International Conference on Molecular Biology and Medicine August 27-28, 2018 Dubai, UAE ; World Congress on Advanced Structural and Molecular Biology 2018 August 22-23, 2018 Rome, Italy ; World Congress on Plant Science and Molecular Biology September 12-13, 2018 Singapore ; 6th Annual Congress on Medicine of Molecules September 17-18, 2018 Abu Dhabi, UAE; 10th Annual Conference on Stem Cell October 08-09, 2018 Zurich, Switzerland; 10th Annual Conference on Stem Cell Regenerative Medicine October 08-09, 2018 Zurich, Switzerland; 6th Asia Pacific Biotechnology Conferences August 15-16, 2018 Singapore; 22nd World Congress on Biotechnology July 10-11, 2018 Bangkok, Thailand, 18thEuropean BiotechnologyConferencesJuly 1 - 4, 2018 Geneva, Switzerland,Biotechnology Conferences.

Related Societies:

Europe:

Spanish Society of Biotechnology, The Pharmaceutical Society of Ireland, Russian Medical Society, Society for Engineering in Agriculture, Society of Microbial Ecology and Disease, Manchester University Pharmaceutical Society, Italian Society of Biochemistry and Molecular Biology, European Society for Precision Engineering and Nanotechnology, Society for Chemical Engineering Biotechnology, Romanian Society of Medical Mycology and Mycotoxicology, New Zealand Plant Protection Society, International Society for Pharmaceutical Engineering, Pharmaceutical Society of Australia,Biotechnology Conferences.

USA:

Mexican Society for Biotechnology and Bioengineering, Society for Biological Engineering, National Society of Agriculture, The Protein Society, Pharmaceutical Marketing Society,,Biotechnology Conferences.

Asia:

Korean Society of Food Science And Technology, Pharmaceutical Society of Singapore, Korean Society of Gene and Cell Therapy, Pharmaceutical Society of Singapore, Indian Society of Nano science And Nanotechnology, Tanta Pharmaceutical Scientific Society (TPSS), Iran Society for Cell Biology, Israel Societies for Experimental Biology, Society for Industrial Microbiology and Biotechnology (SIMB), Malaysian Pharmaceutical Society, Japanese Society for Quantitative Biology, Society for Biotechnology,Biotechnology Conferences.

Track 8: Environmental Biotechnology

Environment biotechnology is applied and used to study the natural environment. Environmental biotechnology could also imply that one try to harness biological process for commercial uses and exploitation. It is "the development, use and regulation of biological systems for remediation of contaminated environment and for environment-friendly processes (green manufacturing technologies and sustainable development). Environmental biotechnology can simply be described as the optimal use of nature, in the form of plants, animals, bacteria, fungi and algae, to produce renewable energy, food and nutrients in a synergistic integrated cycle of profit making processes where the waste of each process becomes the feedstock for another process.

Related: Environmental Biotechnology Conferences | Plant Biotechnology Conferences | Agricultural Biotechnology Conferences | Biotechnology Conferences 2018 | Biotechnology Conferences | Biotechnology Conferences 2018 USA | Biotechnology Conferences|Biotechnology Conferences.

36th International Conference on Environmental Chemistry & Water Resource Management September 24-25, 2018 Chicago, Illinois, USA; 20th International Conference on Environmental Biotechnology and Bioremediation January 15 - 16, 2018 Zurich, Switzerland; International Society for Environmental Biotechnology June 25-28, 2018 Chania, Greece; 10th Annual Conference on Stem Cell Regenerative Medicine October 08-09, 2018 Zurich, Switzerland; 6th Annual Congress on Biology, 6th Annual Congress on Medicine of Molecules September 17-18, 2018 Abu Dhabi, UAE; 8th International Conference and Expo on Nanosciences Nov 26-28,2018 Barcelona, Spain; 6th Asia Pacific Biotechnology Conferences August 15-16, 2018 Singapore; 22nd World Congress on Biotechnology July 10-11, 2018 Bangkok, Thailand, 18thEuropean BiotechnologyConferences July 1 - 4, 2018 Geneva, Switzerland,Biotechnology Conferences.

Related Societies:

Europe:

Spanish Society of Biotechnology, The Pharmaceutical Society of Ireland, Russian Medical Society, Society for Engineering in Agriculture, Society of Microbial Ecology and Disease, Manchester University Pharmaceutical Society, Italian Society of Biochemistry and Molecular Biology, European Society for Precision Engineering and Nanotechnology, Society for Chemical Engineering Biotechnology, Romanian Society of Medical Mycology and Mycotoxicology, New Zealand Plant Protection Society, International Society for Pharmaceutical Engineering, Pharmaceutical Society of Australia,Biotechnology Conferences.

USA:

Mexican Society for Biotechnology and Bioengineering, Society for Biological Engineering, National Society of Agriculture, The Protein Society, Pharmaceutical Marketing Society,Biotechnology Conferences.

Asia:

Korean Society of Food Science And Technology, Pharmaceutical Society of Singapore, Korean Society of Gene and Cell Therapy, Pharmaceutical Society of Singapore, Indian Society of Nano science And Nanotechnology, Tanta Pharmaceutical Scientific Society (TPSS), Iran Society for Cell Biology, Israel Societies for Experimental Biology, Society for Industrial Microbiology and Biotechnology (SIMB), Malaysian Pharmaceutical Society, Japanese Society for Quantitative Biology, Society for Biotechnology,Biotechnology Conferences.

Track 9: Plant and Forest Biotechnology

Plant Biotechnology is a set of techniques used to adapt plants for specific needs or opportunities. Situations that combine multiple needs and opportunities are common, it is prominent in the field of medicine interfacing biotechnology and bioinformatics, the molecular characterization of medicinal plants; molecular farming; and result from chemistry, nanotechnology, pharmacology, agriculture, Biomass and biofuels as well. Plant Biotechnology is the technology which is used for getting modern product with high yield and at faster rate. Biotechnology is being used as a tool to grow trees with special characteristics. When used responsibly, society and the environment can benefit from advanced tree breeding technologies.

Related Conferences: Biotechnology Conferences | Plant Biotechnology | Agricultural Biotechnology | Biotechnology Conferences 2018 | Biotechnology Conferences | Biotechnology Conferences 2018 USA | Biotechnology Conferences|Biotechnology Conferences.

World congress on Plant Pathology & Plant Biotechnology September 24- 25, 2018 Dallas, USA; Agriculture & Horticulture April 08-09, 2019 Prague, Czech Republic; 6th Global Summit on Plant Science October 29-30, 2018 Valencia, Spain; International Association For Plant Biotechnology ConferencesAugust 19-24, 2018 Dublin, Ireland ; Plant Metabolic Engineering Jun 15-16, 2019 Lucca (Barga), Italy. 6th Asia Pacific Biotechnology Conferences August 15-16, 2018 Singapore; 22nd World Congress on Biotechnology July 10-11, 2018 Bangkok, Thailand, 18thEuropean Congress on BiotechnologyJuly 1 - 4, 2018 Geneva, Switzerland,Biotechnology Conferences.

Related Societies:

Europe:

Spanish Society of Biotechnology, The Pharmaceutical Society of Ireland, Russian Medical Society, Society for Engineering in Agriculture, Society of Microbial Ecology and Disease, Manchester University Pharmaceutical Society, Italian Society of Biochemistry and Molecular Biology, European Society for Precision Engineering and Nanotechnology, Society for Chemical Engineering Biotechnology, Romanian Society of Medical Mycology and Mycotoxicology, New Zealand Plant Protection Society, International Society for Pharmaceutical Engineering, Pharmaceutical Society of Australia,Biotechnology Conferences.

USA:

Mexican Society for Biotechnology and Bioengineering, Society for Biological Engineering, National Society of Agriculture, The Protein Society, Pharmaceutical Marketing Society,Biotechnology Conferences.

Asia:

Korean Society of Food Science And Technology, Pharmaceutical Society of Singapore, Korean Society of Gene and Cell Therapy, Pharmaceutical Society of Singapore, Indian Society of Nano science And Nanotechnology, Tanta Pharmaceutical Scientific Society (TPSS), Iran Society for Cell Biology, Israel Societies for Experimental Biology, Society for Industrial Microbiology and Biotechnology (SIMB), Malaysian Pharmaceutical Society, Japanese Society for Quantitative Biology, Society for Biotechnology.,Biotechnology Conferences.

Track 10: Food and Feed Biotechnology

See the original post here:
Biotechnology Conferences | Biotechnology Conferences 2018 ...

Past Conference Information

GlobalConference onPlant ScienceandMolecular Biology2017Report:

Magnus Grouptakes a great pride in declaring the GlobalConference on Plant Science and Molecular Biology (GPMB 2017) which was held in Valencia, Spain, during September 11-13, 2017.

Plant Science Conference 2017witnessed an amalgamation of outstanding speakers who enlightened the crowd with their knowledge and confabulated on various new-fangled topics related to the field of Plant Science and Molecular Biology. The extremely well-known conference hosted by Magnus Group was marked with the attendance of young and brilliant researchers, business delegates and talented student communities representing diverse countries around the world.

For GPMB 2017 Final Program:Click Here

The theme of the conference is Accentuate Innovations and Emerging Novel Research in Plant Sciences. The meeting captivated a vicinity of utilitarian discussions on novel subjects like Plant Physiology and Biochemistry, Plant Biotechnology, Plant Pathology: Mechanisms Of Disease, Applications In Plant Sciences And Plant Research, to mention a few. The three days event implanted a firm relation of upcoming strategies in the field of Plant Science and Molecular Biology with the scientific community. The conceptual and pertinent knowledge shared, will correspondingly foster organizational collaborations to nurture scientific accelerations.

For GPMB 2017 Gallery:Click Here

GPMB 2017Organizing Committee

Prof. Ammann Klaus, University of Bern, Switzerland

Prof. Leif Sundheim, Norwegian Institute of Bioeconomy Research, Norway

Prof. Cornelia Butler Flora, Kansas State University, USA

Dr. Monica Ruffini Castiglione, University of Pisa, Italy

Dr. Samir C. Debnath, St. Johns Research and Development Centre, Canada

The Organizing Committee would like to thank the moderatorsDr. Victoria A Piunova, IBM Almaden Research Center, United States, Dr. Selcuk Aslan, Max Planck Institute of Molecular Plant Physiology, Germany and Dr. Susan Yvonne Jaconis, CSIRO Agriculture, Australia for their contributions which ensued in smooth functioning of the conference.

The highlights of the conference were the keynote forum by prominent scientists,Prof. Klaus Ammann, University of Bern, Switzerland; Prof. Cornelia Butler Flora, Kansas State University, USA; Dr. Monica Ruffini Castiglione, University of Pisa, Italy; Prof. Leif Sundheim, Norwegian Institute of Bioeconomy Research, Norway; Dr. Samir C. Debnath, St. Johns Research and Development Centre, Canada; Dr. Goutam Gupta, Los Alamos National Laboratory, USA; Dr. Elena Rakosy-Tican, Babes-Bolyai University, Romania; Dr. Ivica Djalovic, Institute of Field and Vegetable Crops, Serbia; gave their fruitful contributions in the form of very informative presentations and made the conference a top notch one.

Magnus Groupis privileged to thank the Organizing Committee Members, Keynote speakers, Session chairs on transcribing the sessions, in a varied and variegate manner to make this conference a desirable artifact.

Speakers of GPMB 2017

Day 1: Speakers

Antonova Galina Feodosievna, VN Sukachev Institute of Forest Siberian Branch of Russian Academy of Sciences, Russian Federation

Cezary Piotr Sempruch, Siedlce University of Natural Sciences and Humanities, Poland

Ivan Paponov, Norwegian Institute of Bioeconomy Research, Norway

Malgorzata Adamiec, Adam Mickiewicz University, Institute of Experimental Biology, Poland

Michael Handford, Universidad de Chile, Chile

Natalia Repkina, Institute of Biology Karelian Research Centre of the Russian Academy of Sciences, Russia

Elide Formentin, University of Padova, Italy

Magdalena Opalinska, University of Wroclaw, Poland

Moses Kwame Aidoo, Ben-Gurion University of the Negev, Israel

Yuke He, Shanghai Institutes for Biological Sciences, China

Sameera Omar Bafeel, King Abdulaziz University, Science college, Saudi Arabia

Joerg Fettke, University of Potsdam, Germany

Siti Nor Akmar Abdullah, Universiti Putra Malaysia, Malaysia

Alberto Guillen Bas, University of Valencia, Spain

Carmen Quinonero Lopez, University of Copenhagen, Denmark

Laura Fattorini, Sapienza University of Rome, Italy

Meltem Bayraktar, Ahi Evran University, Turkey

Victoria Cristea, Babes-Bolyai University Cluj-Napoca, Romania

Selcuk Aslan, Max Planck Institute of Molecular Plant Physiology, Germany

Sofia Kourmpetli, Cranfield Soil and AgriFoodInstitute, UK

Seanna Hewitt, Washington State University, USA

Javier Terol Alcayde, Centro de Genomica, IVIA , Spain

Susan Yvonne Jaconis, CSIRO Agriculture, Australia

Magdalena Szechynska-Hebda, Institute of Plant Physiology, Polish Academy of Sciences, Australia

Acga Cheng, University of Malaya, Malaysia

Henrik Toft Simonsen, Technical University of Denmark, Denmark

Yeyun Xin, China National Hybrid Rice Research and Development Center, China

Sandhya Mehrotra, Birla Institute of Technology and Science Pilani, India

Gustavo Souza, Federal University of Pernambuco Bioscience Center, Brazil

Rachel Swee-Suak Ko, Academia Sinica, ABRC/BCST, Taiwan, Province of China

Yougasphree Naidoo, School of Life Sciences, South africa

Julian Witjaksono, The Assessment Institute for Agricultural Technology of Souhteast Sulawesi, Indonesia

Day-1 Posters

Lingling Shang, The Faculty of Agriculture and Food Sciences, Laval University, Canada

Nahaa Miqad Alotaibi, Swansea University, United Kingdom

Layla Al Hijab, West of England Universtiy, United Kingdom

Tomasz Goral, Plant Breeding and Acclimatization Institute NRI, Poland

Mikhail Oliveira Leastro, Instituto Biologico de Sao Paulo, Brazil

Michael Handford, Universidad de Chile, Chile

Polzella Antonella, University of Molise, Italy

Wisniewska Halina, Institute of Plant Genetics Polish Academy of Sciences, Poland

Costel Sarbu, Babes-Bolyai University Cluj-Napoca, Romania

Benjamin Dubois, Walloon Agricultural Research Center (CRA-W), Belgium

Sandra Cichorz, Plant Breeding and Acclimatization Institute - NRI, Poland

Elzbieta Kochanska-Czembor, Plant Breeding and Acclimatization Institute, Poland

Woo Taek Kim, Yonsei University, Republic of Korea

Prashanth Tamizhselvan, Masaryk University, CEITEC MU, Czech Republic

Yun Hee Kim, Gyeongsang National University, Republic of Korea

Nada Bezic, University of Split, Croatia

Havrlentova Michaela, Research Institute for Plant Productio, Slovakia

Seok Keun Cho, Yonsei University, Republic of Korea

Prasanna Angel Deva, Ben Gurion University of the Negev, Israel

Kebede Mesfin Haile, Kangwon National University, Korea

Lidia Kowalska, Plant Breeding and Acclimatization Institute, Poland

Motyleva Svetlana Mikhailivna, FSBSI ARHIBAN, Russian Federation

Paulina Drozdz, Forest Research Institute, Poland

Chul Han An, Korea Research Institute of Bioscience and Biotechnology, Republic of Korea

Jurga Jankauskiene, Nature Research Centre, Lithuania

Day 2: Speakers

Victoria A Piunova, IBM Almaden Research Center, United States

Miroslava Cuperlovic-Culf, National Research Council Canada, Canada

Paola Leonetti, IPSP-CNR, Italy

Giulia Chitarrini, Fondazione Edmund Mach, Italy

Antonio Domenech-Carbo, University of Valencia, Spain

Nurshafika Mohd Sakeh, Universiti Putra Malaysia, Malaysia

Adel Saleh Hussein Al-Abed, National Center for Agricultural Research and Extension, Jordan

Manju Sharma, Amity Institute of Biotechnology, India

Sergio Molinari, IPSP-CNR, Italy

Jaroslava Ovesna, Crop Research institute, czech Rpublic

John B. Carrigan, RebelBio SOSV, Ireland

Bardouki Haido, VIORYL S.A., Greece

Natalia Tomas Marques, Universidade do Algarve, Portugal

Azza M. Salama, Cairo University, Egypt

Chang-Yoon JI, University of Science & Technology, Korea

Kgabo Martha Pofu, Agricultural Research Council, South Africa

Siegfried Zerche, Leibniz-Institute of Vegetable- & Ornamental Crops, Germany

Piergiorgio Stevanato, University of Padova, Italy

Seong Wook Yang, Yonsei University, Republic of Korea

Alexander Hahn, Max Planck Institute for Biophysic, Germany

Klaus Harter, University of Tuebingen, Center for Plant Molecular Biology, Germany

Laigeng Li, Institute of Plant Physiology and Ecology, China

Thomas C Mueller, University of Tennessee, United States

The rest is here:
Plant Biology Conferences 2019 | Plant Biotechnology ...

The U.S. Department of Agriculture's Food Safety and Inspection Service (FSIS) announced that H-E-B Meat Plant, a San Antonio, Tex. establishment, is recalling approximately 1,150 pounds of diced chicken thighs due to misbranding and undeclared allergens. There have been no confirmed reports of adverse reactions due to consumption of these products.

Sid Wainer & Son of New Bedford, MA announced the recall of Jansal Valley brand Dried Chili De Arbol Peppers due to presence of allergen, peanuts. No illnesses have been reported to date in connection with this problem. During repacking, the peanut contamination was discovered in the sealed bulk containers of the product.

TAI FOONG USA of Seattle, WA announced the recall of Royal Asia Shrimp Wonton Noodle Soup due to undeclared egg. One allergic reaction complaint has been confirmed to date, due to consumption of the recalled product.

Prestage Foods, Inc., a St. Pauls, N.C. establishment, is recalling approximately 38,475 pounds of ground turkey that may be contaminated with extraneous materials. The fresh ground turkey was produced on September 25 and 26, 2017. There have been no confirmed reports of adverse reactions due to consumption of these products.

Follow this link:
Biotechnology News, FDA Calendar, Events, Clinical Trial ...

Working in the field of biotechnology, you have a large impact on medicine by helping to advance immunology as well as the development of diagnostic tests and pharmaceutical drugs. And because your field is ever-changing, it is important for you to be able to find biotechnology courses that keep you current. We can help.

Our database of biotechnology courses is a resource that supports your search for continuing medical education. New conferences are constantly being added, so that you can browse through a current and comprehensive list of options. Are you looking for general biotechnology courses, or specific topics like molecular diagnostics, optics, vaccine research or laser technology? We feature a wide range of conferences that have been organized by leaders in the field of biology, chemistry and physical sciences.

If you are starting a search for your next biotechnology course, take a look at our list of upcoming workshops, expos, symposiums, summits and more. For related events, check out our Immunology, Pharmacology and Biochemistry and Molecular Genetics conferences.

Continue reading here:
Biotechnology Medical Conferences 2017 | CME Biotechnology ...

President and Scientific Director, Ontario Institute for Cancer Research and Director, P3G (Public Population Project in Genomics)President and Scientific Director, Ontario Institute for Cancer Research Scientific Director, P3GDr. Thomas J. Hudson is president and scientific director of the Ontario Institute for Cancer Research. He is implementing the institutes strategic plan, working with cancer research institutions across Ontario to leverage existing strengths. The plan focuses on prevention, early diagnosis, cancer targets and new therapeutics. Its innovation platforms include imaging and interventions, bio-repositories and pathology, genomics and high-throughput screening, and informatics and biocomputing. Dr. Hudson is recruiting more than 50 internationally recognized principal investigators.Dr. Hudson was the founder and Director of the McGill University and Genome Quebec Innovation Centre and Assistant-Director of the Whitehead/MIT Center for Genome Research. Dr. Hudson is internationally renowned for his work in genomics. At the Whitehead Institute, Dr. Hudson led the effort to generate dense physical and gene maps of the human and mouse genomes. He is a leader in the development and applications of robotic systems and DNA-chip based methodologies for genome research. In June 1996, he founded the Montreal Genome Centre based at the McGill University Health Centre Research Institute. In 2003, this group expanded to become the McGill University and Genome Quebec Innovation Centre. Dr. Hudson and his team were founding members of the International Haplotype Map Consortium. Dr. Hudsons interests in human genetic diseases focus on the dissection of complex genetic diseases. Disease projects in Dr. Hudsons laboratory included the search for genes predisposing to lupus, inflammatory bowel disease, coronary artery disease, asthma, diabetes and colon cancer. The laboratory also used the DNA-chip technology to characterize breast and ovarian cancer.

In 2007, Dr. Hudson was appointed to the rank of professor (status-only) in the Department of Molecular Genetics at the University of Toronto. He taught in the departments of Human Genetics and Medicine at McGill University and practiced medicine at the McGill University Health Centre Montreal General Hospital.

Dr. Hudson is a fellow of the Royal Society of Canada. He was one of the co-founding members of P3G and is currently serving as its scientific director. He is editor-in-chief of the journal Human Genetics.

The recipient of numerous awards, Dr. Hudson has received the 2005 Achievement of the Year in Healthcare from Macleans magazine, the 2005 Award for Research in Immunology by the Canadian Society for Allergy and Clinical Immunology, the Andr-Dupont 2002 Young Investigator Award given by Quebecs Clinical Research Club, an Investigator Award from the Canadian Institutes of Health Research, a Burroughs-Wellcome Clinician-Scientist Award, The 2002 Prix de la Sant from the Armand-Frappier Foundation, the 2001 Young Scientist Award by the Genetics Society of Canada, the 2000 Scientist of the Year by Radio-Canada, and the 1999 Canadas Top 40 Under 40.

http://oicr.on.ca/person/oicr-investigator/tom-hudson

Visit link:
HudsonAlpha Institute for Biotechnology

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced the release of two abstracts on its drug neratinib that will be presented at the European Society for Medical Oncology (ESMO) 2017 Congress, which will be held September 8 12 in Madrid, Spain. Abstracts are available to the public online on the ESMO website: http://www.esmo.org.

Abstract #1490: Neratinib after trastuzumab-based adjuvant therapy in early stage HER2-positive breast cancer:5-year analysis of the Phase III ExteNET trial.The abstract will be presented as a proffered paper oral session on Friday, September 8.

Abstract #177P:Effects of neratinib on health-related quality of life in early stage HER2-positive breast cancer.The abstract will be displayed as a poster on Monday, September 11.

The ExteNET trial is a double-blind, placebo-controlled, Phase III trial of neratinib versus placebo after adjuvant treatment with trastuzumab (Herceptin) in women with early stage HER2-positive breast cancer.

U.S. Approval of Neratinib (NERLYNX)

Neratinib was approved by the U.S. Food and Drug Administration in July 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX (neratinib) tablets.

About HER2-Positive Breast Cancer

Approximately 20% to 25% of breast cancer tumors over-express the HER2 protein. HER2-positive breast cancer is often more aggressive than other types of breast cancer, increasing the risk of disease progression and death. Although research has shown that trastuzumab can reduce the risk of early stage HER2-positive breast cancer returning after surgery, up to 25% of patients treated with trastuzumab experience recurrence.

Indication

NERLYNX is a tyrosine kinase inhibitor indicated for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy.

To help ensure patients have access to NERLYNX, Puma has implemented the Puma Patient Lynx support program to assist patients and healthcare providers with reimbursement support and referrals to resources that can help with financial assistance.More information on the Puma Patient Lynx program can be found at http://www.NERLYNX.com or 1-855-816-5421.

The full prescribing information for NERLYNX is available at http://www.NERLYNX.com. The recommended dose of NERLYNX is 240 mg (six 40 mg tablets) given orally once daily with food, continuously for one year. Antidiarrheal prophylaxis should be initiated with the first dose of NERLYNX and continued during the first 2 months (56 days) of treatment and as needed thereafter.

Important Safety Information

There are possible side effects of NERLYNX. Patients must contact their doctor right away if they experience any of these symptoms. NERLYNX treatment may be stopped or the dose may be lowered if the patient experiences any of these side effects.

Diarrhea

Diarrheais a common side effect ofNERLYNX. The diarrhea may be severe, and you may get dehydrated. Your healthcare provider should prescribe the medicine loperamide for you during your first 2 cycles (56 days) of NERLYNX and then as needed. To help prevent or reduce diarrhea:

Contact your healthcare provider right away if you have severe diarrhea or if you have diarrhea along with weakness, dizziness or fever.

Liver Problems

Changes in liver function tests are common with NERLYNX. The patients doctor will do tests before starting treatment, monthly during the first 3 months, and then every 3 months as needed during treatment with NERLYNX. NERLYNX treatment may be stopped or the dose may be lowered if your liver tests show severe problems. Symptoms of liver problems may include tiredness, nausea, vomiting, pain in the right upper stomach area (abdomen), fever, rash, itching or yellowing of your skin or whites of your eyes.

Pregnancy

Patients should tell their doctor if they are planning to become pregnant, are pregnant, plan to breastfeed, or are breastfeeding. NERLYNX can harm your unborn baby. Birth control should be used while a patient is receiving NERLYNX and for at least 1 month after the last dose. If patients are exposed to NERLYNX during pregnancy, they must contact their healthcare provider right away.

Common side effects in patients treated with NERLYNX

In clinical studies, the most common side effects seen in patients taking NERLYNX were diarrhea, nausea, abdominal pain, fatigue, vomiting, rash, stomatitis (dry or inflamed mouth, or mouth sores), decreased appetite, muscle spasms, dyspepsia, changes in liver blood test results, nail problems, dry skin, abdominal distention, weight loss and urinary tract infection.

Patients should tell their doctor right away if they are experiencing any side effects. Report side effects to the FDA at 1-800-FDA-1088 orhttp://www.FDA.gov/medwatch. Patients and caregivers may also report side effects to Puma Biotechnology at 1-844-NERLYNX (1-844-637-5969).

Please see Full Prescribing Information, available at http://www.NERLYNX.com.

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. The Company in-licenses the global development and commercialization rights to three drug candidates PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357. NERLYNX (neratinib) is approved for commercial use by prescription in the United States as extended adjuvant therapy for early stage HER2-positive breast cancer following adjuvant trastuzumab-based therapy and is marketed as NERLYNX. Neratinib is a potent irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2 and HER4. Currently, the Company is primarily focused on the commercialization of NERLYNX and the continued development of its other advanced drug candidates directed at the treatment of HER2-positive breast cancer. The Company believes that NERLYNX has clinical application in the potential treatment of several other cancers that over-express or have a mutation in HER2.

Further information about Puma Biotechnology can be found at http://www.pumabiotechnology.com.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding the benefits of NERLYNX and neratinib, the Companys clinical trials and the announcement of data relative to those trials. All forward-looking statements included in this press release involve risks and uncertainties that could cause the Companys actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors, which include, but are not limited to, the fact that the Company has only recently commenced commercialization and shipment of its only FDA approved product; the Companys dependence upon the commercial success of NERLYNX (neratinib); the Companys history of operating losses and its expectation that it will continue to incur losses for the foreseeable future; risks and uncertainties related to the Companys ability to achieve or sustain profitability; the Companys ability to predict its future prospects and forecast its financial performance and growth; failure to obtain sufficient capital to fund the Companys operations; the effectiveness of sales and marketing efforts; the Companys ability to obtain FDA approval or other regulatory approvals in the United States or elsewhere for other indications for neratinib or other product candidates; the challenges associated with conducting and enrolling clinical trials; the risk that the results of clinical trials may not support the Companys drug candidate claims; even if approved, the risk that physicians and patients may not accept or use the Companys products; the Companys reliance on third parties to conduct its clinical trials and to formulate and manufacture its drug candidates; risks pertaining to securities class action, derivative and defamation lawsuits; the Companys dependence on licensed intellectual property; and the other risk factors disclosed in the periodic and current reports filed by the Company with the Securities and Exchange Commission from time to time, including the Companys Quarterly Report on Form 10-Q for the quarter ended June 30, 2017. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company assumes no obligation to update these forward-looking statements, except as required by law.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170830006310/en/

Go here to see the original:
Puma Biotechnology Announces Publication of Abstracts for ESMO 2017 - Markets Insider

As Boulders biotech community continues to thrive and grow, theJennie Smoly Caruthers Biotechnology Buildingdebuted its state-of-the-art E-Wing on Monday.

The 56,340-square-foot E-Wingwill feature next-generation active learning spaces where students learn by doing rather than by being lectured, as well as laboratory space wherecurrent and future faculty in the BioFrontiers Instituteand the Department of Chemicaland Biological Engineering will be able tocontinue their groundbreaking research.

Mondays ribbon-cutting event honored Colorado-based philanthropists John and Anna Sie, whose generous $2 million gift will allow for the creation of an industry co-location space on the E-Wings second floor. The space will be leased to industry partners, allowing local and national biotech companies to bring scientists and resources on-site in order to work side-by-side with university students and researchers.

CU Boulder Chancellor Philip DiStefano and Tom Cech, Nobel Laureate and director of the BioFrontiers Institute, were on hand to officially open the Yuan Yung-Foo Interdisciplinary Bioscience Research Neighborhood and thanked the Sies for their continued support of BioFrontiers and the universitys research mission.

The Sies, whose philanthropic generosity is well known in the state of Colorado and around the world, have provided stalwart support for the BioFrontiers Institute for many years and in many ways, said Cech, a Distinguished Professor of chemistry and biochemistry at CU Boulder. We are truly grateful for their most recent commitment to providing much-needed research facilities where our talented researchers, students and industry partners work together to unravel the complexities of biology with an ultimate goal of enhancing human health and welfare.

Anna and John are among CUs most generous donorstheir gifts are always transformational, DiStefano said. "With their support, we are achieving our vision to become a leader in addressing the humanitarian, social and technological challenges of the 21st century."

Construction on the $32 million E-wing broke ground in March 2016, aided by $15 million in funding from the state of Colorado.

For more information on the E-Wing, visit the BioFrontiers Institutes website.

More here:
Biotechnology building debuts state-of-the-art E-Wing - CU Boulder Today

Your May 17 article about genetic engineering [Facts, Fears and the Future of Food] is so chock-full of glib falsehoods that I hardly know where to begin. I would have far more respect for the science behind biotechnology if it didnt depend so heavily on half-truths, double standards, unwarranted assumptions, blurred distinctions and conflicts of interest.

Jack Britt says that the same microorganisms move genes between species both in nature and in genetic engineering, and therefore the methods are the same. This is half true. In the latter, various techniques are employed to either bypass or weaken the natural immunity of the organism being manipulated, often literally forcing the DNA into the cells in ways that would never occur in nature. Stating that many organisms are naturally GMO, and therefore implying that we have carte blanche to do whatever we wish, isnt just a stretch, its a whopper.

Britt and Leah McGrath emphasize the precision of these techniques. Again, this is a perversion of the truth. In fact, this is merely a precision of abstractions, because the living organism is then going to move these genes around in ways that cant possibly be controlled or predicted. The only way to even begin to achieve complete control or precision would be to kill the organism, which would obviously be counterproductive. A technology that treats living organisms as though they were dead has extremely questionable scientific validity, not to mention morality.

Both the tone and title of the article perpetuate the same old scientific myths about biotechnology: The facts are with the scientists, the fears (beliefs) are with the uninformed public, and the future of food requires the widespread adoption of these techniques. The public is misinformed, largely because news media like the Xpress have allowed themselves to be used as soapboxes by academic cheerleaders for corporate interests.

As long as we continue to assume that:1. The deterministic gene weve been taught in school and through the media is real.2. The kind of science we now have (which is mostly technology rather than science proper) is the only science possible. And3. Everything a scientist says is scientific by definition,

we will continue to make catastrophic mistakes.

Substantive criticisms of biotechnology do exist, but for some reason, they almost never find their way into the mass media. The opposition only seems weak because its strongest arguments are ignored.

Andy Shaw Easton, Md.

Editors note: Freelance writer Nick Wilson responds in part:I thank you for your passionate response. I appreciate criticism and view it as an opportunity to learn through grappling with different perspectives. Ultimately, Im more than happy to admit my past errors if I come to a new understanding that falls more in line with what I believe to be true. If it comes to my awareness that I have put forth falsehoods, Id absolutely like to remedy that. This is to say that my perspectives are evolving, not fixed. Its important to me to keep learning and growing in the pursuit of truth.

Link:
Letter: Perpetuating 'scientific' myths about biotechnology - Mountain Xpress

Advertisement

Shares last traded at $93.95 barely above $87.37, the 50 day moving average and which is well above the 200 day moving average of $61.78. The 50 day moving average went up by +7.53% whereas the 200 day average was up by +52.06%. 820K shares changed hands by the end of trading on Friday. Overall, volume was down 80.71% under the stocks normal daily volume.

Traders are more bullish on Puma Biotechnology Inc of late looking at the fall in short interest. The firm had a fall in short interest between July 31, 2017 and August 15, 2017 of -0.12%. Short interest decreased 7,361 over that timeframe. The days to cover decreased to 6.0 and the percentage of shorted shares was 0.17% on August 15.

Here is the rundown on market activity for Puma Biotechnology Inc (NASDAQ:PBYI). Richard Paul Bryce, SR VP, CLINICAL RESEARCH & DEV sold $435,500 worth of shares at an average price of $87.10 on July 3rd. Bryce now owns $2,546,543 of stock as recorded in a recent Form 4 SEC filing.

Here are a few other firms who have also updated their positions. Janus Capital Management LLC divested its stake by shedding 2,714 shares a decrease of 0.1% from 12/31/2016 to 03/31/2017. Janus Capital Management LLC currently owns 2,209,599 shares worth $82,195,000. The total value of its holdings increased 21.0%. Rock Springs Capital Management Lp expanded its investment by buying 91,500 shares an increase of 96.8% as of 06/30/2017. Rock Springs Capital Management Lp claims 186,000 shares valued at $16,256,000. The value of the position overall is up by 362.5%.

Ghost Tree Capital, LLC reduced its holdings by selling 75,000 shares a decrease of 33.3% in the quarter. Ghost Tree Capital, LLC now holds 150,000 shares with a value of $13,110,000. The value of the position overall is up by 56.6%. As of the end of the quarter Graticule Asia Macro Advisors LLC had sold 6,200 shares trimming its holdings by 13.4%. The value of the investment in (PBYI) went from $1,726,000 to $3,514,000 a change of 103.6% quarter over quarter.

July 18 investment analysts at Credit Suisse maintained a stock rating of Outperform and raised the price target to $118.00 from $111.00.

In the market the company is trading up by 1.57% since yesterdays close of $92.5. In the last earnings report the EPS was $-8.14 and is expected to be $-8.68 for the current year with 37,205,000 shares outstanding. Analysts expect next quarters EPS to be $-2.09 and the next full year EPS is projected to be $-4.71.

Puma Biotechnology, Inc., launched on September 15, 2010, is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the global development and commercialization rights to the three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357. Its neratinib has clinical application in the treatment of several other cancers as well, including non-small cell lung cancer (NSCLC), and other tumor types that over-express or have a mutation in HER2..

Originally posted here:
Puma Biotechnology Inc (NASDAQ:PBYI) Stock Closed 7.5% Above Its 50 Day Average - Modern Readers

Collecting leachate from a capped landfill site. Credit: Bangor University

Far from being a load of rubbish, landfill sites should be considered one of the great untapped resources in the search for new enzymes for biotechnology, and could fuel more efficient biofuel production.

A new research paper in mSphere by biologists at Bangor and Liverpool universities has for the first time identified the enzymes which degrade natural materials such as paper and clothing in landfill sites.

James McDonald, from Bangor University's School of Biological Sciences, who led the research said:

"There is a current impetus to search for new enzymes to improve biomass conversion processes. Our hypothesis is that, due to the volume of waste materials they hold, landfill sites represent a repository of unexplored biomass-degrading diversity. There is significant potential to identify new enzymes of ecological and biological significance."

Cellulose and lignin occur naturally in plant-based materials and take longer to decompose than other waste products. As a result of this, the majority of landfill waste consists of lignin and cellulose. In their plant form, they can be used as the basis for biofuel production, and identifying more effective enzymes for this process would improve the yield from this source.

Scientists have been searching for a number of years for the most effective enzymes which break down the cellulose and lignin within the residual natural fibres. The obvious place to search has been in the rumen of sheep and cows, who eat grasses, and the guts of also other plant eaters such as elephants and termites.

Surprisingly perhaps, landfill sites share many of the same characteristics as the digestive systems of these animals: they are dark, anoxic or un-oxygenated spaces, with a high content of cellulose. It was therefore to landfill sites, which are artificially created 'systems', that this group of scientists turned to find new plant-degrading enzymes.

Within in the paper, the authors describe how they used the liquid or 'leachate' within landfill sites as a source of microbes to decompose cotton, and analysed not only the families or taxa of bacteria, but also identified which bacteria produce groups of enzymes to degrade cellulose.

Emma Ransom-Jones, a postdoctoral researcher at Bangor University, and lead author of the study said:

"Understanding exactly how the cellulose and lignin decompose, and the sources of the active enzymes in the process will enable us to determine ways to improve the degradation of waste in landfill sites, and potentially use this as a source for biofuel production."

Explore further: Enzyme shows promise for efficiently converting plant biomass to biofuels

More information: Emma Ransom-Jones et al. Lignocellulose-Degrading Microbial Communities in Landfill Sites Represent a Repository of Unexplored Biomass-Degrading Diversity, mSphere (2017). DOI: 10.1128/mSphere.00300-17

See the rest here:
Biotechnology researchers turn to landfill sites - Phys.Org

Photo: Contributed Photo / Hearst Connecticut Media

Sonics Executive Vice President Lauren Soloff, left, stands with CEC Co-Chairs Joe McGee and William Tong at the Sonics headquarters in Newtown, Conn., in August 2017.

Sonics Executive Vice President Lauren Soloff, left, stands with CEC Co-Chairs Joe McGee and William Tong at the Sonics headquarters in Newtown, Conn., in August 2017.

Connecticut a major player in growing biotechnology sector

The growing biotechnology corridor in the region and improved collaboration between government and manufacturing companies are among the major focuses of the state Commission on Economic Competitiveness, said the co-chairmen of the commission during a recent visit to a Newtown manufacturer.

Life sciences is an area that can really become a major part of Connecticuts growing economy, said Joe McGee, co-chairman of the commission and also the vice president of public policy and programs at Stamford-based Business Council of Fairfield County. Precision medicine and its potential is an economic driver in the state.

McGee, along with co-chairman and state Rep. William Tong, D-147, last week toured Sonics & Materials, a Newtown-based manufacturer of ultrasonic liquid processors, plastic assembly equipment and metal welding systems. Formed in 1969, Sonics has developed a line of advanced ultrasonic liquid processors for applications in DNA sequencing and nanoparticle dispersion.

Its just unbelievable that a company, sitting in Newtown, Connecticut, has a machine that is critical for the sequencing of DNA, McGee said. It just shows you the viability of the Connecticut manufacturing sector.

McGee and Tong said Connecticut is a major player in a burgeoning biotechnology corridor that stretches from New York City into the Nutmeg State. Companies such as Sonics, which employs 75 people, and larger players such as Mount Sinai in Stamford, Boehringer Ingelheim in Ridgefield and Jackson Laboratory in Farmington make Connecticut a force in the life sciences industry, they said.

Tong said the New York City Department of Economic Development recently met with the Connecticut Health Data Collaborative and announced it is investing money to have biotechnology firms migrate into Connecticut.

They need Connecticut and we need them, Tong said. Its a big component of Connecticuts economic future.

Tong said the growing field will help the state reach its lofty expectations associated with the CT 500 program, the goal of which is to create 500,000 private-sector jobs in the state in the next 25 years.

McGee said the biotechnology corridor has a broad reach and it has only recently been targeted as a major economic driver for the state. The Commission on Economic Competitiveness, or CEC, is performing an asset analysis of the industry.

Its one of those things thats been hiding in plain sight, McGee said. There are a lot of places here of significance.

The CEC was created by the state Legislature in 2015 and is made up of lawmakers and private sector leaders with the goal of strengthening and improving the states economic competitiveness.

Lauren Soloff, executive vice president at Sonics, said McGee and Tong talked at length with employees and had a lunch outside after the tour. Soloff, a Westport resident, said the co-chairmen discussed how companies such as Sonics can partner with community colleges and vocational schools to strengthen the curriculum for advanced manufacturing programs.

Its nice to shine a bright light on some of the positive things happening in Connecticut, she said. It was an extremely positive meeting. They are both realists, but optimistic. It was one of the more upbeat visits weve ever had.

cbosak@hearstmediact.com; 203-731-3338

See the rest here:
Connecticut a major player in growing biotechnology sector - Danbury News Times

Evotec's immunology spin-out Topas Therapeutics has inked a multi-year R&D collaboration with pharma major Eli Lilly. The initial focus of research, which will be financed by Eli Lilly, is on identification of antigens that specifically induce a T regulatory cell response in inflammatory and auto-immune disorders.

Using the company's nanoparticle platform, the collaboration will initially focuson identification of inflammatory or autoimmunity-inducing antigens that trigger immune tolerance through activation of regulatory T cells responses in liver stem cells. Specifically, Topas targets peptide-loaded nanoparticles towards liver sinusoidal endothelial cells (LSECs), which are one of the body's premier sites to induce tolerance against bloodborne antigens by generating peptide-specific regulatory T cells.

Under the terms of the agreement, Topas will be responsible for conducting pre-clinical proof-of-principle studies in collaboration with Lilly to generate drug candidates. According to the contract, Lilly may licence and advance development of all candidates originating from the collaboration. Topas will receive R&D funding and participate in the future success of any compounds in-licensed by Lilly. Financial details of the collaboration have not been disclosed.

Topas Therapeutics was spun out in March from Evotec's subsidiary Bionamics GmbH. The company, which uses a groundbreaking nanoparticle technology to target autoimmune and inflammatory diseases via the induction of antigen-specific immune tolerance in the liver, has14m of venture capital fromEpidarex Capital, EMBL Ventures and Gimv in its pockets. Evotec is its largest shareholder.

Topas has several candidate peptides under preclinical development, the most advanced expected to come to the clinic in 2018 is intended to treat multiple sclerosis.

Read the original here:
Topas Therapeutics lands option deal with Eli Lilly - European Biotechnology

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Wave Life Sciences Ltd. (NASDAQ:WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced the publication of a new paper in the September issue of Nature Biotechnology. The paper describes a breakthrough method to produce antisense oligonucleotide (ASO) therapeutics with high stereochemical purity as well as rational drug design to control pharmacologic properties in nucleic acid therapeutics drug development more broadly. This publicationof Waves stereopure chemistry platform represents a significant scientific advancement for the oligonucleotide field.

The paper, entitled "Control of phosphorothioate stereochemistry substantially increases the efficacy of antisense oligonucleotides," details a proprietary synthesis process developed by Wave. By applying this method, Wave was able to overcome previous barriers to the scalable synthesis of stereochemically pure oligonucleotides.

These findings represent a breakthrough in the nucleic acid field, said Chandra Vargeese, Ph.D., head of Drug Discovery at Wave Life Sciences. This paper outlines early foundational principles discovered by Wave to engage RNase H1 that can be applied to any ASO sequence. We have demonstrated that stereochemistry plays a central role in oligonucleotide drug design, with the potential to improve stability, duration of activity and specificity. With continued advancements in our proprietary synthesis process, we have developed a highly efficient manufacturing system that may allow for these key findings to translate into next generation nucleic acid therapeutics. We continue to leverage these initial findings to further build our knowledge base and expand our platform capabilities beyond antisense, including our ongoing work in exon skipping, single stranded RNAi and other modalities.

Wave's researchers synthesized rationally designed stereopure isomers of mipomersen, an FDA approved drug comprised of 524,288 stereoisomers. These researchers demonstrated that phosphorothioate stereochemistry substantially impacts the pharmacologic properties of ASOs. Furthermore, their work identified a stereochemical code that can be rationally designed in the stereopure ASOs that promotes targeted RNA cleavage by RNase H1, and that provides a more durable response in mice than is achieved by stereorandom ASOs. Waves research also demonstrated that this stereochemical code improved pharmacologic properties both with mipomersen and with a second sequence (conjugated with GalNAc) that targets APOC3. This stereochemical platform provides a foundation for Wave's current pre-clinical and clinical programs, including two recently initiated trials in Huntington's disease (PRECISION-HD1 and PRECISION-HD2).

"These findings provide a powerful demonstration of Wave's stereopure oligonucleotide platform and its potential to rationally design therapies targeting currently untreatable genetic conditions," said Greg Verdine, founder, board member of Wave Life Sciences. "The ability for the first time to exert precise, synthetically programmable control over the chemistry and stereochemistry of ASOs, and the pharmacologic benefits observed for stereochemical optimization as demonstrated in this paper, offer a compelling basis for Wave's novel approach toward advancing safer and more effective nucleic acid therapies."

About Wave Life Sciences

Wave Life Sciences is a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases. Our chemistry platform enables the creation of highly specific, well characterized oligonucleotides designed to deliver superior efficacy and safety across multiple therapeutic modalities. Our pipeline is initially focused on neurological disorders and extends across several other therapeutic areas.

Forward Looking Information

This press release contains forward-looking statements, including statements relating to the significance of the paper; the importance of the papers findings in the field of nucleic acid therapeutics; the distinguishing features of Waves drug development platform and the potential benefits thereof. These statements may be identified by words such as believe, expect, may, plan, potential, will and similar expressions, and are based on current beliefs and expectations. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including risks and uncertainties associated with Waves stereopure chemistry platform, the drug development and regulatory approval process; and the commercialization, development and acceptance of therapies with new technologies, as well as other risks and uncertainties that are described in the Risk Factors section of Waves most recent annual or quarterly report filed with the U.S. Securities and Exchange Commission. Any forward-looking statements speak only as of the date of this press release and the parties assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Originally posted here:
Wave Life Sciences Announces Publication of Paper in Nature ... - Business Wire (press release)

Shares ofProShares Ultra Nasdaq Biotechnology (BIB) have seen the needle move3.41% or 1.75 in the most recent session. TheNASDAQ listed companysaw a recent bid of $53.03 on83915 volume.

Strictly technical traders typically dont pay a whole lot of attention to fundamental factors such as value, competition, or company management. Technical analysts want to figure out trends based on indicators, charts, and prior price data. These types of traders are usually highly active and hold positions for short periods of time in order to capitalize on short-term price fluctuations. Active traders may be quick to unload a position if it does not pan out as expected. Technicians often pay a great deal of attention to support and resistance levels. These are levels where traders believe a specific stock will either see a bounce or a pullback.

Digging deeping into the ProShares Ultra Nasdaq Biotechnology (BIB) s technical indicators, we note that the Williams Percent Range or 14 day Williams %R currently sits at -54.70. The Williams %R oscillates in a range from 0 to -100. A reading between 0 and -20 would point to an overbought situation. A reading from -80 to -100 would signal an oversold situation. The Williams %R was developed by Larry Williams. This is a momentum indicator that is the inverse of the Fast Stochastic Oscillator.

ProShares Ultra Nasdaq Biotechnology (BIB) currently has a 14-day Commodity Channel Index (CCI) of -31.41. Active investors may choose to use this technical indicator as a stock evaluation tool. Used as a coincident indicator, the CCI reading above +100 would reflect strong price action which may signal an uptrend. On the flip side, a reading below -100 may signal a downtrend reflecting weak price action. Using the CCI as a leading indicator, technical analysts may use a +100 reading as an overbought signal and a -100 reading as an oversold indicator, suggesting a trend reversal.

Currently, the 14-day ADX for ProShares Ultra Nasdaq Biotechnology (BIB) is sitting at 20.96. Generally speaking, an ADX value from 0-25 would indicate an absent or weak trend. A value of 25-50 would support a strong trend. A value of 50-75 would identify a very strong trend, and a value of 75-100 would lead to an extremely strong trend. ADX is used to gauge trend strength but not trend direction. Traders often add the Plus Directional Indicator (+DI) and Minus Directional Indicator (-DI) to identify the direction of a trend.

The RSI, or Relative Strength Index, is a widely used technical momentum indicator that compares price movement over time. The RSI was created by J. Welles Wilder who was striving to measure whether or not a stock was overbought or oversold. The RSI may be useful for spotting abnormal price activity and volatility. The RSI oscillates on a scale from 0 to 100. The normal reading of a stock will fall in the range of 30 to 70. A reading over 70 would indicate that the stock is overbought, and possibly overvalued. A reading under 30 may indicate that the stock is oversold, and possibly undervalued. After a recent check, the 14-day RSI for ProShares Ultra Nasdaq Biotechnologyis currently at 47.24, the 7-day stands at 50.69, and the 3-day is sitting at 71.69.

See the original post here:
Shares Seesawing on Volume: ProShares Ultra Nasdaq Biotechnology (BIB) - Morgan Research